Cassava Sciences Management
Management criteria checks 1/4
Cassava Sciences' CEO is Rick Barry, appointed in Sep 2024, has a tenure of 1.33 years. total yearly compensation is $16.73M, comprised of 1.8% salary and 98.2% bonuses, including company stock and options. directly owns 1.94% of the company’s shares, worth MX$33.33M. The average tenure of the management team and the board of directors is 1.2 years and 4.6 years respectively.
Key information
Rick Barry
Chief executive officer
US$16.7m
Total compensation
| CEO salary percentage | 1.85% |
| CEO tenure | 1.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 1.2yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$106m |
| Jun 30 2025 | n/a | n/a | -US$123m |
| Mar 31 2025 | n/a | n/a | -US$73m |
| Dec 31 2024 | US$17m | US$309k | -US$24m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$1m | n/a | -US$97m |
Compensation vs Market: Rick's total compensation ($USD16.73M) is above average for companies of similar size in the MX market ($USD20.89K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Barry (66 yo)
Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$16.73m | 1.94% MX$ 33.3m | |
| Chief Financial Officer | 7.3yrs | US$3.85m | 0.024% MX$ 408.7k | |
| Chief Operating & Legal Officer | 3.3yrs | US$1.27m | 0.028% MX$ 487.7k | |
| Senior Vice President of Technology | 21yrs | no data | no data | |
| Senior Vice President of Technical Operations | 26yrs | no data | no data | |
| Chief Business Officer & Chief Commercial Officer | 1.2yrs | no data | no data | |
| Chief Clinical Development Officer | 1.2yrs | no data | no data | |
| Senior Vice President of Neuroscience | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 1yr | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Head of Regulatory Affairs | less than a year | no data | no data |
Experienced Management: SAVA *'s management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.6yrs | US$16.73m | 1.94% MX$ 33.3m | |
| Independent Director | 18.1yrs | US$212.91k | 0.0021% MX$ 35.5k | |
| Independent Director | 27.6yrs | US$212.91k | 0.014% MX$ 244.3k | |
| Member of Scientific Advisory Board | 11.3yrs | US$558.31k | no data | |
| Independent Director | 22.8yrs | US$314.37k | 0.022% MX$ 377.3k | |
| Independent Chairman | 2.1yrs | US$212.91k | 0% MX$ 0 | |
| Independent Director | 2.1yrs | US$212.91k | 0.018% MX$ 305.6k | |
| Independent Director | 2.1yrs | US$212.91k | 0% MX$ 0 | |
| Independent Director | less than a year | no data | no data |
Experienced Board: SAVA *'s board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 12:17 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cassava Sciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Fraser | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Elemer Piros | Lucid Capital Markets |